(R)-Moxestrol

Synonyms: (R)-R 2858; RU 16117
(R)-Moxestrol ((R)-R 2858; RU 16117) 是一种具有口服活性的弱雌激素受体 (ER) 部分激动剂–拮抗剂,可与雌激素受体结合形成快速解离的复合物并降低雌激素和催乳素受体水平,在低剂量下表现弱雌激素效应,在高剂量或与 Estradiol (E2) (MS-S93344) 竞争时表现抗雌激素作用,可用于乳腺癌和绝经后雌激素缺乏 (更年期症状、严重骨质疏松症) 的相关研究。
产品编号: MS-J58773 CAS No.: 61665-15-4 分子式: C21H26O3 分子量: 326.43
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

(R)-Moxestrol ((R)-R 2858; RU 16117) 是一种具有口服活性的弱雌激素受体 (ER) 部分激动剂–拮抗剂,可与雌激素受体结合形成快速解离的复合物并降低雌激素和催乳素受体水平,在低剂量下表现弱雌激素效应,在高剂量或与 Estradiol (E2) (MS-S93344) 竞争时表现抗雌激素作用,可用于乳腺癌和绝经后雌激素缺乏 (更年期症状、严重骨质疏松症) 的相关研究。

生物实验数据

生物活性 (R)-Moxestrol ((R)-R 2858; RU 16117) is an orally active weak estrogen receptor (ER) partial agonist–antagonist that binds to the estrogen receptor to form a rapidly dissociating complex and reduces estrogen and prolactin receptor levels, exhibiting weak estrogenic effects at low doses and antiestrogenic effects at high doses or when competing with Estradiol (E2) (MS-S93344), and can be used in research related to breast cancer and postmenopausal estrogen deficiency (menopausal symptoms, severe osteoporosis).
体外研究
(In Vitro)

RU 16117 可未成熟小鼠子宫中形成胞质雌激素受体 (ER) 复合物。

体内研究
(In Vivo)

(R)-Moxestrol (2-24 μg;腹腔注射;每日给药;持续 4 周) 可呈剂量依赖性抑制 DMBA (MS-Y05966) 诱导的雌性大鼠乳腺癌生长。
(R)-Moxestrol (0.1-50 μg;皮下注射) 可强效抑制大鼠动情周期的多项指标。
(R)-Moxestrol (1-100 μg;皮下注射;单次注射,连续给药 3 天;持续释放 72 小时) 在未成熟雌性瑞士小鼠中发挥弱雌激素作用。

Animal Model: Sprague-Dawley (female, 50-55 days old, DMBA-induced mammary carcinoma)
Dosage: 2 μg; 8 μg; 24 μg
Administration: i.p.; daily; 4 weeks
Result: Exhibited little effect on tumor number or total tumor area, caused a slight increase in average tumor size due to 11 new tumors developing, and showed no significant reduction in [3H]E2, [3H]R5020, or 125I-labeled ovine PRL receptor levels in tumor tissue at 2 μg daily.
Inhibited tumor number by 45% compared to controls, had minimal effect on total tumor area, caused a slight increase in average tumor size due to 4 new tumors developing, showed no significant reduction in [3H]E2, [3H]R5020, or 125I-labeled ovine PRL receptor levels in tumor tissue, and increased plasma PRL levels relative to controls at 8 μg daily.
Reduced tumor number by 65% compared to controls, caused marked reduction in total tumor area and average tumor size (only 3 new tumors developed), reduced [3H]E2 binding in tumor tissue from 2.3 pmoles/g (controls) to 0.3 pmoles/g, significantly reduced 125I-labeled ovine PRL specific binding in tumor tissue, resulted in low progesterone receptor levels in 4 of 6 tumors accompanying reduced estrogen and prolactin receptor levels, and increased plasma PRL levels relative to controls at 24 μg daily.
Animal Model: Sprague-Dawley (female, 200-225 g, with 2-3 prior 4-day estrous cycles)
Dosage: 0.1-50 μg (various regimens)
Administration: s.c.; twice daily; 2-4 days; s.c.; single dose; s.c.; twice on single day
Result: Caused a 1-day delay in vaginal cornification with 0.5 μg twice-daily 4-day treatment.
Caused a 4.5 day delay in vaginal cornification with 5.0 μg twice-daily 4-day treatment.
Caused a 14.8 day delay in vaginal cornification with 50 μg twice-daily 4-day treatment.
Caused a 1.6 day delay in vaginal cornification with 0.5 μg twice-daily 2-day (estrus + diestrus 1) treatment.
Caused a 1.1 day delay in vaginal cornification with 1.5 μg twice-daily 2-day (estrus + diestrus 1) treatment.
Caused a 4.9 day delay in vaginal cornification with 4.5 μg twice-daily 2-day (estrus + diestrus 1) treatment.
Caused a 5.8 day delay in vaginal cornification with 13.5 μg twice-daily 2-day (estrus + diestrus 1) treatment.
Reduced uterine weight to 522 mg (0.5 μg), 358 mg (1.5 μg), 372 mg (4.5 μg), 327 mg (13.5 μg) at 1600 h on expected proestrus (control: 756 mg) with twice-daily 2-day (estrus + diestrus 1) treatment.
Reduced uterine weight to 489 mg (0.5 μg), 362 mg (1.5 μg), 282 mg (4.5 μg), 294 mg (13.5 μg) at 1000 h on expected estrus (control: 453 mg) with twice-daily 2-day (estrus + diestrus 1) treatment.
Completely inhibited ovulation (0/10 rats ovulating) with all doses ≥0.5 μg twice-daily 2-day (estrus + diestrus 1) treatment (control: 10/10).
Reduced plasma LH to 407 ng/mL (control: 888 ng/mL) with 0.5 μg twice-daily estrus-only treatment.
Reduced plasma LH to 103 ng/mL, plasma PRL to 23 ng/mL (control: 203 ng/mL), and uterine weight to 426 mg (control: 590 mg) with 2.5 μg twice-daily estrus-only treatment.
Completely inhibited the preovulatory LH and FSH peaks with 5 μg single dose injected at 2000 h proestrus, 0800 h estrus, or 2000 h estrus.
Depressed the plasma LH response to LHRH by 60% with 0.5 μg twice-daily 2-day (estrus + diestrus 1) treatment.
Almost completely inhibited the plasma LH response to LHRH with doses ≥ 1.5 μg twice-daily 2-day (estrus + diestrus 1) treatment.
Animal Model: Swiss mice (immature 18-day old female)
Dosage: 1 μg; 10 μg; 100 μg (single s.c.); 1 μg; 3 μg; 10 μg (daily s.c. x3); 30 μg (total s.c. over 3 days); 3 μg; 10 μg (continuous silastic implant over 72 hours)
Administration: s.c. (single injection); s.c. (daily for 3 consecutive days); silastic implant (continuous release over 72 hours)
Result: Increased uterine wet weight to a similar extent as 1 μg estradiol or moxestrol at 6 hours, but returned to control levels by 48 hours with a single 10 μg s.c. dose.
Maintained uterine weight increase for 48 hours with a single 100 μg s.c. dose.
Produced maximum uterine weight increase within 24 hours with three daily 1-3 μg s.c. doses, with no further effect from subsequent injections.
Required a daily 10 μg s.c. dose to match the effect of 0.1 μg estradiol.
Increased uterine weight 8-10-fold over 72 hours with silastic implants releasing 3 μg or 10 μg.
Depleted cytosolic ER by 1 hour, increased nuclear ER, and allowed cytosolic ER replenishment to control or above levels by 24 hours with a single 1 μg s.c. dose.
Kept cytosolic ER levels low for at least 24 hours with a single 100 μg s.c. dose.
Induced a 24-hour PR increase similar to estradiol, but PR levels returned to control by 48 hours with a single 1 μg s.c. dose.
Maintained PR at 3-4 times control at 48 hours, dropping to twice control by day 3 and control by day 5 with a single 100 μg s.c. dose.
Inhibited the estradiol-induced uterine weight increase by 30%, and antagonized estradiol-induced ER replenishment and PR induction with a total 30 μg s.c. dose over 3 days; lower doses were ineffective.

化学信息

分子量 326.43
分子式 C21H26O3
CAS No. 61665-15-4
别名 (R)-R 2858; RU 16117

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础